2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2547

NIP-565, a Novel JAK1-Selective Inhibitor, for the Treatment of Rheumatoid Arthritis
Abstract Number: 848

Nitroglycerin Patch Application in Systemic Sclerosis: Evaluation By Laser Doppler Imaging
Abstract Number: 3058

NMR-Based Metabolomics Provides New Insights into the Inflammatory Processes in Takayasu Arteritis
Abstract Number: 1594

No Association of Anti-Citrullinated Peptide Antibodies with Coronary Artery Calcification in Two Rheumatoid Arthritis Cohorts without Clinical Cardiovascular Disease
Abstract Number: 2686

No Clear Association Between the Presence of Ultrasound Synovitis and Patient Reported Outcomes in Rheumatoid Arthritis Patients in Remission
Abstract Number: 2499

No More No Shows: Improving the Appointment Reminder System at an Urban County Hospital Outpatient Rheumatology Clinic
Abstract Number: 454

No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis
Abstract Number: 64

Nociceptive Flexion Reflex Threshold: Possible Surrogate Marker of Symptom Severity in Fibromyalgia
Abstract Number: 940

NOD2-Associated Autoinflammatory Disease: Therapy and Outcomes
Abstract Number: 498

Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Abstract Number: 2184

Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual
Abstract Number: 1629

Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis
Abstract Number: 2855

Non-Response to Antitnf Treatment in Psoriatic Arthritis Can be Predicted By an Objective Automated Measurement of Fluorescence-Signal Intensities in Fluorescence-Optical Imaging Technique – the First Interims Analysis of the Xplore-Study
Abstract Number: 1767

Noninvasive Assessment of Macrophage Activation in Experimental Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves As a Surrogate of Disease Activity
Abstract Number: 2034

Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].